CLSN - Celsion shares fall 8% despite earnings beat

Despite reporting EPS this morning for 2020 that beat analyst expectations and revenue that was in-line, Celsion (CLSN) shares are struggling this afternoon.The company says that its phase 1/2 OVATION 2 study for its ovarian cancer immunotherapy GEN-1 is one-third complete with enrollment expected to finish by the end of the year.GEN-1 has FDA Fast Track designation.Last month, the company sent a letter to shareholders indicating it would stop following patients in the phase 3 OPTIMA study of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, in several cancer indications.In January, Celsion filed a provisional U.S. patent application for a DNA-based vaccine to treat a broad range of infections, including coronaviruses.Celsion shares are down 8.2% to $2.08 in afternoon trading.

For further details see:

Celsion shares fall 8% despite earnings beat